These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17966008)

  • 1. Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: a randomized placebo-controlled, double-blind study.
    Lapidus LJ; Ponzer S; Elvin A; Levander C; Lärfars G; Rosfors S; de Bri E
    Acta Orthop; 2007 Aug; 78(4):528-35. PubMed ID: 17966008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study.
    Lapidus LJ; Rosfors S; Ponzer S; Levander C; Elvin A; Lärfars G; de Bri E
    J Orthop Trauma; 2007 Jan; 21(1):52-7. PubMed ID: 17211270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin).
    Dahl OE; Andreassen G; Aspelin T; Müller C; Mathiesen P; Nyhus S; Abdelnoor M; Solhaug JH; Arnesen H
    Thromb Haemost; 1997 Jan; 77(1):26-31. PubMed ID: 9031444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
    Eriksson BI; Lassen MR;
    Arch Intern Med; 2003 Jun; 163(11):1337-42. PubMed ID: 12796070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
    Marlovits S; Striessnig G; Schuster R; Stocker R; Luxl M; Trattnig S; Vécsei V
    Arthroscopy; 2007 Jul; 23(7):696-702. PubMed ID: 17637403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
    Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
    J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
    Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
    Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis.
    Kerr J; Linkins LA
    Thromb Haemost; 2010 Jan; 103(1):123-8. PubMed ID: 20062935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
    Ennis RS
    J South Orthop Assoc; 2003; 12(1):10-7. PubMed ID: 12735619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.
    Kucher N; Leizorovicz A; Vaitkus PT; Cohen AT; Turpie AG; Olsson CG; Goldhaber SZ
    Arch Intern Med; 2005 Feb; 165(3):341-5. PubMed ID: 15710801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization.
    Lassen MR; Borris LC; Nakov RL
    N Engl J Med; 2002 Sep; 347(10):726-30. PubMed ID: 12213943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.
    Lassen MR; Borris LC; Anderson BS; Jensen HP; Skejø Bro HP; Andersen G; Petersen AO; Siem P; Hørlyck E; Jensen BV; Thomsen PB; Hansen BR; Erin-Madsen J; Møller JC; Rotwitt L; Christensen F; Nielsen JB; Jørgensen PS; Paaske B; Tørholm C; Hvidt P; Jensen NK; Nielsen AB; Appelquist E; Tjalve E
    Thromb Res; 1998 Mar; 89(6):281-7. PubMed ID: 9669750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
    Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?
    Prescrire Int; 2000 Feb; 9(45):197-8. PubMed ID: 11503794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
    Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R
    Arch Intern Med; 2000 Jul; 160(14):2208-15. PubMed ID: 10904465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.